Vertex Pharmaceuticals (VRTX)

Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises.

The Nasdaq 100 Index remains under pressure after forming a death cross pattern a few weeks ago. It has retreated to $18,257, down by over 17.8% from its highest point this year.

Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating anti-competitive practices.

CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation.

A group of S&P 500 stocks have remained resilient as tariffs and earnings concerns cause the market to drop. Future gains may be limited.

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.